Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Kynamro Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Kynamro (mipomersen injection for SC use) Prior Authorization Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prescription benefit prior authorization for Kynamro, an adjunctive lipid-lowering therapy for adults with homozygous familial hypercholesterolemia (HoFH). Approval applies to patients initiating or continuing therapy and requires specialist prescribing or consultation, defined clinical criteria, and renewal every 12 months.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyKynamro (mipomersen injection for SC use) Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateSep 14, 2015
    Next Review DateN/A
    Key ActionObtain prior authorization and ensure Kynamro is prescribed by or used in consultation with a qualified specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    ≥18 yearsMinimum authorization age
    >500 mg/dLUntreated LDL-C threshold
    ≥300 mg/dLTreated LDL-C threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    200 mg weeklyRecommended dose

    Coverage Criteria

    Initial and continuing therapy for HoFH

    Approve Kynamro for 12 months when ALL of the following criteria are met.

    Kynamro HoFH authorization

    • Age: The patient is aged ≥18 years.≥18 years
    • HoFH diagnosis

      • Genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus.Two mutant alleles
      • Untreated LDL-C: The patient has an untreated LDL-C level greater than 500 mg/dL before treatment with antihyperlipidemic agents.>500 mg/dL
      • Treated LDL-C: The patient has a treated LDL-C level of at least 300 mg/dL after antihyperlipidemic treatment but before agents such as Repatha or Juxtapid.≥300 mg/dL
      • Clinical manifestations: The patient has clinical manifestations of HoFH, such as cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
    • Repatha response or LDL-receptor status

      • Inadequate Repatha response: The patient has tried Repatha (evolocumab) and had an inadequate response according to the prescribing physician.
      • Two LDL-receptor-negative alleles: The patient is known to have two LDL-receptor-negative alleles.Two alleles
    • Statin therapy or intolerance

      • Inadequate response to high-intensity statin: The patient has tried atorvastatin ≥40 mg daily or rosuvastatin ≥20 mg daily, as a single-entity or combination product, for ≥8 continuous weeks and the LDL-C level remains ≥70 mg/dL.≥8 continuous weeks; LDL-C ≥70 mg/dL
      • Statin intolerance

        • Rhabdomyolysis: The patient experienced statin-related rhabdomyolysis, with associated muscle pain, weakness, tenderness, acute renal failure, and/or elevated creatine kinase, such as CK ≥10 times the upper limit of normal.CK example ≥10× the upper limit of normal
        • Skeletal muscle symptoms with both statins: The patient experienced skeletal-related muscle symptoms during separate trials of both atorvastatin and rosuvastatin, and the symptoms resolved upon discontinuation of each respective statin therapy.

          Symptoms may include myopathy or myalgia; products may be single-entity or combination products.

    • Specialist involvement: Kynamro is prescribed by, or in consultation with, a cardiologist, an endocrinologist, or a physician who focuses on cardiovascular risk management and/or lipid disorders.
    • Concurrent statin when tolerated: If able to tolerate statins, the patient continues to receive the maximum tolerated dose of a statin while receiving Kynamro.Maximum tolerated statin dose

    Coverage is not recommended for concurrent use of Kynamro with Juxtapid (lomitapide), Praluent (alirocumab), or Repatha (evolocumab). Coverage is also not recommended for patients with heterozygous familial hypercholesterolemia (HeFH) or other forms of hyperlipidemia, including primary hyperlipidemia or mixed dyslipidemia, when HoFH is not established.

    Coverage is not recommended when the circumstances do not meet the listed recommended authorization criteria. The criteria may be updated as new published data become available.

    Clinical Thresholds and Dosing Criteria

    Untreated LDL-C
    Qualifying threshold>500 mg/dL
    TimingBefore treatment with antihyperlipidemic agents
    MeasurementUntreated low-density lipoprotein cholesterol (LDL-C)
    Treated LDL-C
    Qualifying threshold≥300 mg/dL
    TimingAfter antihyperlipidemic treatment but before Repatha or Juxtapid
    MeasurementTreated low-density lipoprotein cholesterol (LDL-C)

    Provider Requirements and Coverage Restrictions

    Prior Authorization

    Prior Authorization and Specialist Requirement

    Prior authorization is recommended for Kynamro prescription benefit coverage. Because HoFH management requires specialized expertise, Kynamro must be prescribed by, or given in consultation with, a physician who specializes in the condition being treated.

    • Approvals are provided for 12 months.
    • Criteria apply to patients initiating Kynamro and to patients currently receiving Kynamro.
    • The prescriber or consultant must be a cardiologist, endocrinologist, or physician focused on cardiovascular risk management and/or lipid disorders.
    Step Therapy

    Required Prior Lipid-Lowering Therapy

    Before Kynamro coverage, the patient must meet a qualifying prior lipid-lowering therapy pathway: inadequate response to Repatha or documentation of two LDL-receptor-negative alleles, together with appropriate high-intensity statin therapy or qualifying statin intolerance.

    • The patient has tried Repatha (evolocumab) and had an inadequate response according to the prescribing physician, or is known to have two LDL-receptor-negative alleles.

    Therapy Background

    Kynamro (mipomersen) is an apolipoprotein B-100 synthesis inhibitor used as an adjunct to lipid-modifying therapy and diet in adults with homozygous familial hypercholesterolemia (HoFH). It is intended to reduce LDL-C and other atherogenic lipid parameters in this rare inherited disorder, which is associated with severely impaired LDL clearance and markedly elevated circulating LDL-C.

    Clinical Definitions

    Homozygous familial hypercholesterolemia (HoFH)
    ConditionA rare inherited disorder characterized by markedly elevated circulating LDL-C
    Underlying problemLDL-C is not adequately removed from the body
    Diagnostic contextDiagnosis may be established using genetic or clinical criteria
    Genetic or clinical HoFH diagnosis
    Genetic criterionTwo mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus
    Laboratory criteriaUntreated LDL-C >500 mg/dL or treated LDL-C ≥300 mg/dL
    Clinical or family-history context

    Initial Therapy

    Initial therapy for HoFH

    Approve Kynamro for 12 months when ALL criteria for adult HoFH are met.

    Initial Kynamro therapy

    • Age: The patient is aged ≥18 years.≥18 years
    • HoFH diagnosis

      • Qualifying HoFH diagnosis

        • Genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus.Two mutant alleles

    Continuing Therapy

    Continuing therapy

    For patients currently receiving Kynamro, apply the same authorization criteria; approve renewal for 12 months when ALL criteria are met.

    Continuing Kynamro therapy: The patient continues to meet all requirements for Kynamro coverage: age ≥18 years; a qualifying HoFH diagnosis; the Repatha inadequate-response or two LDL-receptor-negative-alleles requirement; the high-intensity statin response or statin-intolerance requirement; specialist prescribing or consultation; and continued maximum tolerated statin therapy if able to tolerate statins.Approval period: 12 months

    The criteria apply to patients currently receiving Kynamro as well as those initiating therapy.

    Required Treatment Sequence

    StepRequirementException
    1Try one high-intensity statin: atorvastatin ≥40 mg daily or rosuvastatin ≥20 mg daily, as a single-entity or combination product, for ≥8 continuous weeks. LDL-C must remain ≥70 mg/dL.Step may be bypassed if the patient meets the policy’s statin-intolerance criteria.
    StepRequirementException
    2Try Repatha (evolocumab) and document an inadequate response according to the prescribing physician.Step may be bypassed if the patient is known to have two LDL-receptor-negative alleles.

    Kynamro Dose and Quantity Limits

    Kynamro standard dose
    Standard dose200 mg
    AdministrationSubcutaneous injection
    FrequencyOnce weekly
    Kynamro dose for patients weighing less than 50 kg
    Reduced dose160 mg
    Patient weightLess than 50 kg
    Administration and frequencySubcutaneous injection once weekly

    Administration Site of Care

    Note

    Supervise the first injection in the office

    The first injection administered by the patient or caregiver should occur under the guidance and supervision of an appropriately qualified healthcare professional.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyKynamro (mipomersen injection for SC use) Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateSep 14, 2015
    Next Review DateN/A
    Key ActionObtain prior authorization and ensure Kynamro is prescribed by or used in consultation with a qualified specialist.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Dosing CriteriaProvider Requirements and Coverage RestrictionsTherapy BackgroundClinical DefinitionsInitial TherapyContinuing TherapyRequired Treatment SequenceKynamro Dose and Quantity LimitsAdministration Site of Care
    High-intensity atorvastatin dose
    Required dose≥40 mg daily
    MedicationAtorvastatin
    Therapy classificationHigh-intensity statin therapy
    High-intensity rosuvastatin dose
    Required dose≥20 mg daily
    MedicationRosuvastatin (Crestor)
    Therapy classificationHigh-intensity statin therapy
    High-intensity statin trial
    Required duration≥8 continuous weeks
    TherapyQualifying high-intensity statin therapy
    Qualifying agentsAtorvastatin ≥40 mg daily or rosuvastatin ≥20 mg daily
    LDL-C after statin therapy
    Qualifying threshold≥70 mg/dL
    TimingAfter the qualifying high-intensity statin trial
    Coverage significanceLDL-C remains at or above this level after at least 8 continuous weeks of therapy
    Creatine kinase for rhabdomyolysis example
    Example qualifying elevation≥10 times the upper limit of normal
    Laboratory measureCreatine kinase (CK)
    Clinical contextUsed as an example finding in statin-related rhabdomyolysis
  1. The patient has tried atorvastatin ≥40 mg daily or rosuvastatin (Crestor) ≥20 mg daily for ≥8 continuous weeks, with LDL-C remaining ≥70 mg/dL; or the patient is statin intolerant.
  2. Qualifying statin intolerance includes statin-related rhabdomyolysis, or skeletal-related muscle symptoms occurring during separate atorvastatin and rosuvastatin trials that resolved after discontinuation of each respective therapy.
  3. If able to tolerate statins, the patient must continue the maximum tolerated statin dose while receiving Kynamro.
  4. Documentation Required

    Documentation Requirements

    No documentation is required for this policy, and there is no automation requirement.

    • Documentation: None required.
    • Automation: None.
    Denial Risk

    Concurrent Lipid-Lowering Therapy Not Covered

    Coverage is not recommended for concurrent use of Kynamro with Juxtapid, Praluent, or Repatha.

    • Kynamro has not been studied concomitantly with Juxtapid (lomitapide).
    • Repatha and Praluent are PCSK9 inhibitors and have not been studied concomitantly with Kynamro therapy.
    Denial Risk

    HeFH Not Recommended for Coverage

    Coverage is not recommended for Kynamro in patients with heterozygous familial hypercholesterolemia (HeFH).

    • Kynamro safety and effectiveness have not been established in patients with hypercholesterolemia who do not have HoFH.
    • Other options for HeFH may have a better benefit-to-risk profile, including statins, Praluent, Repatha, and Zetia.
    Denial Risk

    Other Hyperlipidemia Not Recommended for Coverage

    Coverage is not recommended for Kynamro in other forms of hyperlipidemia, including primary hyperlipidemia and mixed dyslipidemia.

    • Kynamro use has not been established in patients with hypercholesterolemia who do not have HoFH.
    Denial Risk

    Criteria Not Met

    Coverage is not recommended when the circumstances do not meet the policy's Recommended Authorization Criteria.

    • This restriction applies to circumstances not otherwise listed in the Recommended Authorization Criteria.
    • Criteria may be updated as new published data become available.
    The qualifying LDL-C elevation is considered with cutaneous or tendon xanthoma before age 10 years, or untreated LDL-C consistent with HeFH in both parents
    Statin-related rhabdomyolysis
    DefinitionStatin-induced muscle breakdown
    Signs and symptomsMuscle pain, weakness, tenderness, acute renal failure, and/or elevated creatine kinase
    Example laboratory findingCreatine kinase ≥10 times the upper limit of normal
    Untreated LDL-C is greater than 500 mg/dL before treatment with antihyperlipidemic agents.>500 mg/dL
  5. Treated LDL-C is at least 300 mg/dL after antihyperlipidemic treatment but before agents such as Repatha or Juxtapid.≥300 mg/dL
  6. Clinical manifestations of HoFH are present, such as cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
  7. Repatha response or LDL-receptor status

    • The patient has tried Repatha (evolocumab) and had an inadequate response according to the prescribing physician.
    • The patient is known to have two LDL-receptor-negative alleles.Two alleles
  8. Statin response or intolerance

    • The patient has tried atorvastatin ≥40 mg daily or rosuvastatin ≥20 mg daily, as a single-entity or combination product, for ≥8 continuous weeks and the LDL-C level remains ≥70 mg/dL.≥8 continuous weeks; LDL-C ≥70 mg/dL
    • Statin intolerance

      • The patient experienced statin-related rhabdomyolysis, with associated muscle symptoms, acute renal failure, and/or elevated CK such as ≥10 times the upper limit of normal.CK example ≥10× the upper limit of normal
      • The patient experienced skeletal-related muscle symptoms during separate trials of both atorvastatin and rosuvastatin, and the symptoms resolved upon discontinuation of each respective statin therapy.

        Symptoms may include myopathy or myalgia; products may be single-entity or combination products.

  9. Specialist involvement: Kynamro is prescribed by, or in consultation with, a cardiologist, an endocrinologist, or a physician who focuses on cardiovascular risk management and/or lipid disorders.
  10. Concurrent statin when tolerated: If able to tolerate statins, the patient continues to receive the maximum tolerated dose of a statin while receiving Kynamro.Maximum tolerated statin dose